Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT00876395. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination With Trastuzumab and Paclitaxel, as First Line Therapy in Women With HER2 Positive Locally Advanced or Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this Phase III study was to confirm the value of adding everolimus to weekly paclitaxel and trastuzumab as treatment of HER2-overexpressing metastatic breast cancer.
Study identification
- NCT ID
- NCT00876395
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 719 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 10, 2009 (Actual)
- Primary completion
- May 30, 2014 (Actual)
- Completion
- Oct 23, 2017 (Actual)
- Last update posted
- Dec 19, 2018
2009 – 2017
United States locations
- U.S. sites
- 25
- U.S. states
- 14
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of South Alabama / Mitchell Cancer Institute Dept. of Mitchell Cancer Inst. | Mobile | Alabama | 36688 | — |
| Ironwood Cancer and Research Centers | Chandler | Arizona | 85224 | — |
| Highlands Oncology Group | Fayetteville | Arkansas | 72703 | — |
| Comprehensive Blood and Cancer Center Dept. of CBCC (2) | Bakersfield | California | 93309 | — |
| St. Jude Heritage Medical Group Virginia Crosson Cancer Center | Fullerton | California | 92835 | — |
| University of California at Los Angeles Dept. of UCLA | Los Angeles | California | 90095 | — |
| Ventura County Hematology and Oncology | Oxnard | California | 93030 | — |
| Cancer Care Associates Medical Group Dept. of CCA | Redondo Beach | California | 90277 | — |
| Santa Barbara Hematolgy Oncology Medical Group Dept.ofSantaBarbaraHem/Onc | Santa Barbara | California | 93105 | — |
| Central Coast Medical Oncology Corporation Onc Dept | Santa Maria | California | 93454 | — |
| Rocky Mountain Cancer Centers RMCC - Denver-Midtown (3) | Greenwood Village | Colorado | — | — |
| Florida Cancer Specialists Dept.of FloridaCancerSpec. (2) | Fort Myers | Florida | 33901 | — |
| Florida Cancer Specialists | West Palm Beach | Florida | 33401 | — |
| Central Indiana Cancer Centers CICC - East (3) | Indianapolis | Indiana | 46227 | — |
| Kansas City Cancer Center Dept. of KCCC | Overland Park | Kansas | 66210 | — |
| University of Nebraska Medical Center Unv Nebraska Med Ctr (2) | Omaha | Nebraska | 68198 | — |
| New York Oncology Hematology NYOH Amsterdam | Albany | New York | 12208 | — |
| Beth Israel Medical Center Dept.ofBeth Israel Med. Ctr(2) | New York | New York | 10003 | — |
| Northwest Cancer Specialists Vancouver Cancer Center (3) | Portland | Oregon | 97210 | — |
| Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(5) | Nashville | Tennessee | 37203 | — |
| Texas Oncology Charles A. Sammons Cancer Ctr | Dallas | Texas | 75246 | — |
| Texas Oncology P A SC-Austin | Dallas | Texas | 75251 | — |
| Tyler Cancer Center Dept.ofTylerCancerCtr. (2) | Tyler | Texas | 75702 | — |
| Virginia Oncology Associates SC | Norfolk | Virginia | 23502 | — |
| Virginia Cancer Institute VCI (3) | Richmond | Virginia | 23230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 115 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00876395, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 19, 2018 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00876395 live on ClinicalTrials.gov.